IBDEI1XB ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30723,0)
;;=E83.42^^123^1583^21
;;^UTILITY(U,$J,358.3,30723,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30723,1,3,0)
;;=3^Hypomagnesemia
;;^UTILITY(U,$J,358.3,30723,1,4,0)
;;=4^E83.42
;;^UTILITY(U,$J,358.3,30723,2)
;;=^5003003
;;^UTILITY(U,$J,358.3,30724,0)
;;=N25.1^^123^1583^25
;;^UTILITY(U,$J,358.3,30724,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30724,1,3,0)
;;=3^Nephrogenic Diabetes Insipidus
;;^UTILITY(U,$J,358.3,30724,1,4,0)
;;=4^N25.1
;;^UTILITY(U,$J,358.3,30724,2)
;;=^5015616
;;^UTILITY(U,$J,358.3,30725,0)
;;=E27.49^^123^1583^2
;;^UTILITY(U,$J,358.3,30725,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30725,1,3,0)
;;=3^Adrenocortical Insufficiency,Other
;;^UTILITY(U,$J,358.3,30725,1,4,0)
;;=4^E27.49
;;^UTILITY(U,$J,358.3,30725,2)
;;=^5002743
;;^UTILITY(U,$J,358.3,30726,0)
;;=E72.09^^123^1583^4
;;^UTILITY(U,$J,358.3,30726,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30726,1,3,0)
;;=3^Amino-Acid Transport Disorders,Other
;;^UTILITY(U,$J,358.3,30726,1,4,0)
;;=4^E72.09
;;^UTILITY(U,$J,358.3,30726,2)
;;=^5002895
;;^UTILITY(U,$J,358.3,30727,0)
;;=N25.89^^123^1583^23
;;^UTILITY(U,$J,358.3,30727,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30727,1,3,0)
;;=3^Impaired Renal Tubular Function Disorders,Other
;;^UTILITY(U,$J,358.3,30727,1,4,0)
;;=4^N25.89
;;^UTILITY(U,$J,358.3,30727,2)
;;=^5015618
;;^UTILITY(U,$J,358.3,30728,0)
;;=E26.89^^123^1583^12
;;^UTILITY(U,$J,358.3,30728,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30728,1,3,0)
;;=3^Hyperaldosteronism,Other
;;^UTILITY(U,$J,358.3,30728,1,4,0)
;;=4^E26.89
;;^UTILITY(U,$J,358.3,30728,2)
;;=^5002737
;;^UTILITY(U,$J,358.3,30729,0)
;;=N25.81^^123^1583^29
;;^UTILITY(U,$J,358.3,30729,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30729,1,3,0)
;;=3^Secondary Hyperparathyroidism of Renal Origin
;;^UTILITY(U,$J,358.3,30729,1,4,0)
;;=4^N25.81
;;^UTILITY(U,$J,358.3,30729,2)
;;=^5015617
;;^UTILITY(U,$J,358.3,30730,0)
;;=E22.2^^123^1583^28
;;^UTILITY(U,$J,358.3,30730,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30730,1,3,0)
;;=3^SIADH
;;^UTILITY(U,$J,358.3,30730,1,4,0)
;;=4^E22.2
;;^UTILITY(U,$J,358.3,30730,2)
;;=^5002718
;;^UTILITY(U,$J,358.3,30731,0)
;;=E87.79^^123^1583^10
;;^UTILITY(U,$J,358.3,30731,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30731,1,3,0)
;;=3^Fluid Overload,Other
;;^UTILITY(U,$J,358.3,30731,1,4,0)
;;=4^E87.79
;;^UTILITY(U,$J,358.3,30731,2)
;;=^5003025
;;^UTILITY(U,$J,358.3,30732,0)
;;=E21.0^^123^1583^27
;;^UTILITY(U,$J,358.3,30732,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30732,1,3,0)
;;=3^Primary Hyperparathyroidism
;;^UTILITY(U,$J,358.3,30732,1,4,0)
;;=4^E21.0
;;^UTILITY(U,$J,358.3,30732,2)
;;=^331439
;;^UTILITY(U,$J,358.3,30733,0)
;;=E87.71^^123^1583^30
;;^UTILITY(U,$J,358.3,30733,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30733,1,3,0)
;;=3^Transfusion Associated Circulatory Overload
;;^UTILITY(U,$J,358.3,30733,1,4,0)
;;=4^E87.71
;;^UTILITY(U,$J,358.3,30733,2)
;;=^5003024
;;^UTILITY(U,$J,358.3,30734,0)
;;=D63.1^^123^1584^1
;;^UTILITY(U,$J,358.3,30734,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30734,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,30734,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,30734,2)
;;=^332908
;;^UTILITY(U,$J,358.3,30735,0)
;;=I12.0^^123^1584^9
;;^UTILITY(U,$J,358.3,30735,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XB 3770 printed Oct 16, 2024@18:18:25 Page 2
IBDEI1XB ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30723,0)
+2 ;;=E83.42^^123^1583^21
+3 ;;^UTILITY(U,$J,358.3,30723,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,30723,1,3,0)
+6 ;;=3^Hypomagnesemia
+7 ;;^UTILITY(U,$J,358.3,30723,1,4,0)
+8 ;;=4^E83.42
+9 ;;^UTILITY(U,$J,358.3,30723,2)
+10 ;;=^5003003
+11 ;;^UTILITY(U,$J,358.3,30724,0)
+12 ;;=N25.1^^123^1583^25
+13 ;;^UTILITY(U,$J,358.3,30724,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,30724,1,3,0)
+16 ;;=3^Nephrogenic Diabetes Insipidus
+17 ;;^UTILITY(U,$J,358.3,30724,1,4,0)
+18 ;;=4^N25.1
+19 ;;^UTILITY(U,$J,358.3,30724,2)
+20 ;;=^5015616
+21 ;;^UTILITY(U,$J,358.3,30725,0)
+22 ;;=E27.49^^123^1583^2
+23 ;;^UTILITY(U,$J,358.3,30725,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,30725,1,3,0)
+26 ;;=3^Adrenocortical Insufficiency,Other
+27 ;;^UTILITY(U,$J,358.3,30725,1,4,0)
+28 ;;=4^E27.49
+29 ;;^UTILITY(U,$J,358.3,30725,2)
+30 ;;=^5002743
+31 ;;^UTILITY(U,$J,358.3,30726,0)
+32 ;;=E72.09^^123^1583^4
+33 ;;^UTILITY(U,$J,358.3,30726,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,30726,1,3,0)
+36 ;;=3^Amino-Acid Transport Disorders,Other
+37 ;;^UTILITY(U,$J,358.3,30726,1,4,0)
+38 ;;=4^E72.09
+39 ;;^UTILITY(U,$J,358.3,30726,2)
+40 ;;=^5002895
+41 ;;^UTILITY(U,$J,358.3,30727,0)
+42 ;;=N25.89^^123^1583^23
+43 ;;^UTILITY(U,$J,358.3,30727,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,30727,1,3,0)
+46 ;;=3^Impaired Renal Tubular Function Disorders,Other
+47 ;;^UTILITY(U,$J,358.3,30727,1,4,0)
+48 ;;=4^N25.89
+49 ;;^UTILITY(U,$J,358.3,30727,2)
+50 ;;=^5015618
+51 ;;^UTILITY(U,$J,358.3,30728,0)
+52 ;;=E26.89^^123^1583^12
+53 ;;^UTILITY(U,$J,358.3,30728,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,30728,1,3,0)
+56 ;;=3^Hyperaldosteronism,Other
+57 ;;^UTILITY(U,$J,358.3,30728,1,4,0)
+58 ;;=4^E26.89
+59 ;;^UTILITY(U,$J,358.3,30728,2)
+60 ;;=^5002737
+61 ;;^UTILITY(U,$J,358.3,30729,0)
+62 ;;=N25.81^^123^1583^29
+63 ;;^UTILITY(U,$J,358.3,30729,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,30729,1,3,0)
+66 ;;=3^Secondary Hyperparathyroidism of Renal Origin
+67 ;;^UTILITY(U,$J,358.3,30729,1,4,0)
+68 ;;=4^N25.81
+69 ;;^UTILITY(U,$J,358.3,30729,2)
+70 ;;=^5015617
+71 ;;^UTILITY(U,$J,358.3,30730,0)
+72 ;;=E22.2^^123^1583^28
+73 ;;^UTILITY(U,$J,358.3,30730,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,30730,1,3,0)
+76 ;;=3^SIADH
+77 ;;^UTILITY(U,$J,358.3,30730,1,4,0)
+78 ;;=4^E22.2
+79 ;;^UTILITY(U,$J,358.3,30730,2)
+80 ;;=^5002718
+81 ;;^UTILITY(U,$J,358.3,30731,0)
+82 ;;=E87.79^^123^1583^10
+83 ;;^UTILITY(U,$J,358.3,30731,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,30731,1,3,0)
+86 ;;=3^Fluid Overload,Other
+87 ;;^UTILITY(U,$J,358.3,30731,1,4,0)
+88 ;;=4^E87.79
+89 ;;^UTILITY(U,$J,358.3,30731,2)
+90 ;;=^5003025
+91 ;;^UTILITY(U,$J,358.3,30732,0)
+92 ;;=E21.0^^123^1583^27
+93 ;;^UTILITY(U,$J,358.3,30732,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,30732,1,3,0)
+96 ;;=3^Primary Hyperparathyroidism
+97 ;;^UTILITY(U,$J,358.3,30732,1,4,0)
+98 ;;=4^E21.0
+99 ;;^UTILITY(U,$J,358.3,30732,2)
+100 ;;=^331439
+101 ;;^UTILITY(U,$J,358.3,30733,0)
+102 ;;=E87.71^^123^1583^30
+103 ;;^UTILITY(U,$J,358.3,30733,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,30733,1,3,0)
+106 ;;=3^Transfusion Associated Circulatory Overload
+107 ;;^UTILITY(U,$J,358.3,30733,1,4,0)
+108 ;;=4^E87.71
+109 ;;^UTILITY(U,$J,358.3,30733,2)
+110 ;;=^5003024
+111 ;;^UTILITY(U,$J,358.3,30734,0)
+112 ;;=D63.1^^123^1584^1
+113 ;;^UTILITY(U,$J,358.3,30734,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,30734,1,3,0)
+116 ;;=3^Anemia in Chronic Kidney Disease
+117 ;;^UTILITY(U,$J,358.3,30734,1,4,0)
+118 ;;=4^D63.1
+119 ;;^UTILITY(U,$J,358.3,30734,2)
+120 ;;=^332908
+121 ;;^UTILITY(U,$J,358.3,30735,0)
+122 ;;=I12.0^^123^1584^9
+123 ;;^UTILITY(U,$J,358.3,30735,1,0)
+124 ;;=^358.31IA^4^2
